Advent Life Sciences
VC
INVESTOR TYPE
Active
STATUS
6
PROFESSIONALS
66
INVESTMENTS
22
PORTFOLIO
31
EXITS
Description
Advent Life Sciences is a venture capital firm which seeks to invest in early and mid-stage life sciences firms. The firm focuses in new drug discovery, small molecules, biologics and new modalities, med tech, enabling technologies and vaccines.
Website
Investor Status
Actively Seeking New Investments
Year Founded
2009
Primary Investor Type
Venture Capital
Primary Office
- 158-160 North Gower Street
- London NW1 2ND
- England, United Kingdom
+44 020 0000 0000
Advent Life Sciences Investments (66)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| MiroBio | 07-Oct-2019 | Early Stage VC | 000.00 | Biotechnology | Startup | 0000000 00000 00 |
| 00000 000000000000 | 27-Jun-2019 | 00000 00000 | 00.000 | Drug Discovery | Startup | |
| 000000 0000000 | 20-Jun-2019 | 00000 00000 | 00000 | Diagnostic Equipment | Generating Revenue | 0000000 00000 00 |
| 000000-000 | 04-Jun-2019 | 0000 00000 | 00.000 | Drug Discovery | Generating Revenue | 000000 000000 00.0 |
| 0000000 0000000000 | 10-Apr-2019 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 000000 000000 00.0 |
| 0000 00000000000 | 13-Dec-2018 | 00000 00000 | 000.00 | Biotechnology | Clinical Trials - Phase 1 | 000000 000000 00.0 |
| 00000 000000000000 | 29-Aug-2018 | 00000 00000 | 000.00 | Biotechnology | Generating Revenue | 000000 0000000 |
| 0000000 0000000000 | 11-Apr-2018 | 00000 00000 | 000.00 | Surgical Devices | Generating Revenue/Not Profitable | 0000000 00000 00 |
| Macrolide Pharmaceuticals | 02-Apr-2018 | Early Stage VC | 0000 | Drug Discovery | Pre-Clinical Trials | 000000 000000 00.0 |
| Iterum Therapeutics | 16-Feb-2018 | Early Stage VC | 000.00 | Drug Discovery | Generating Revenue/Not Profitable | 0000000 00000 00 |
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Advent Life Sciences’s full profile, request a free trial.
Advent Life Sciences Exits (31)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Vestagen | 01-Jul-2019 | Out of Business | Completed |
|
|
| 0000000 0000000000 | 31-Oct-2018 | 000 | 00000 | Completed |
|
| 000000 00000000000 | 25-May-2018 | 000 | 0000 | Completed |
|
| 0000000000 | 04-Apr-2018 | 000000000000000000 | 00000 | Completed |
|
| 0000000 000 | 30-Jun-2017 | 000000000 00000000 | Completed |
|
|
| 0000000000 0000000 | 01-May-2016 | 000000000000000000 | Completed |
|
|
| 0000000 00000 0000 | 26-Aug-2015 | 000000000000000000 | 00000 | Completed |
|
| 000000000 | 20-Aug-2015 | 000000000000000000 | Completed |
|
|
| Cellnovo | 10-Jul-2015 | IPO | 000.00 | Completed |
|
| Biocartis | 27-Apr-2015 | IPO | 00000 | Completed |
|
Advent Life Sciences Fund Performance
| Fund Name | Vintage | Size | Dry Powder | DPI | RVPI | TVPI | IRR |
|---|
This information is reserved for PitchBook Platform accredited users. To explore Advent Life Sciences‘s full profile, request access.
Request full access to PitchBookAdvent Life Sciences Team (19)
1 Former Team Member
You’re viewing 5 of 19 team members. Get the full list »Advent Life Sciences Co-Investors (76)
| Name | With | Exits | Lead Partner |
|---|---|---|---|
| Henri Termeer | 3 | 0 | |
| Longitude Capital | 0 | 0 | |
| OrbiMed | 0 | 0 | |
| Canaan Partners | 0 | 0 | |
| Forbion | 0 | 0 |